Drug profile · INN
brensocatib
BRINSUPRI
brensocatib (BRINSUPRI) is a dipeptidyl peptidase i inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — brensocatib
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
brensocatib (BRINSUPRI) is a dipeptidyl peptidase i inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dipeptidyl peptidase I inhibitor
Primary target: Dipeptidyl peptidase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is brensocatib?
brensocatib (BRINSUPRI) is a dipeptidyl peptidase i inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for brensocatib?
BRINSUPRI is a marketed brand name for brensocatib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brensocatib?
brensocatib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.